Hong Kong Stock Movement | YIDU TECH (02158) Surges Over 14% as AI Expected to Empower Clinical Trials, Subsidiary Wins Bid for SMR001 Eye Drops Phase III Clinical Research Project

Stock News
Yesterday

YIDU TECH (02158) surged over 14% in late trading, and as of press time, the stock was up 12.89% to HK$6.57 with a trading volume of HK$466 million. On the news front, YIDU TECH recently announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. has won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drops Phase III clinical research project, with a total project value of approximately RMB 55.82 million. Notably, on September 16, the 2025 Tencent Digital Ecosystem Conference Medical Special Session was held. YIDU TECH's senior solution expert Shi Cheng delivered a keynote speech on "AI Empowering the Full Process of Clinical Trials," combining YIDU TECH's years of technological accumulation and practical cases to comprehensively explain the pathways through which AI can effectively improve the efficiency and quality of clinical trials from technical support and scenario implementation to ecosystem construction, driving high-quality industry development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10